ホーム › 大うつ病性障害 › テキサス › Houston
Houston、TXにおける大うつ病性障害の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、大うつ病性障害に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
被験者募集中第3相
- Baylor College of Medicine, Houston
- Houston Clinical Trials LLC, Bellaire · 7マイル先
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
被験者募集中第3相
- DM Clinical Research, Houston
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
被験者募集中第3相
- John S Dunn Behavioral Sciences Center at UTHealth Houston, Houston
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
被験者募集中第3相
- Brain Health Consultants and TMS Center, Houston
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
被験者募集中第3相
- Vanda Investigational Site, Houston
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
被験者募集中第1相健康なボランティア歓迎
- Wells Medicine, Houston
- Texas A&M (Houston Methodist Hospital Location), Houston
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
被験者募集中第2相
- Baylor College of Medicine, Houston
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
被験者募集中
- CHI St. Luke's Health Baylor College of Medicine Med. Ctr, Houston
- The Methodist Hospital, Houston
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
被験者募集中第2相
- Elevate Synapsis, LLC, Atascocita · 20マイル先
- Synapsis Bio, Atascocita · 20マイル先
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Bellaire · 7マイル先
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Houston
- Neurocrine Clinical Site, Bellaire · 7マイル先
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
被験者募集中第3相
- Clinical Research Site, Houston
- Clinical Research Site, Bellaire · 7マイル先
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
被験者募集中第2相
- Houston Clinical Trials - Bellaire /ID# 277551, Bellaire · 7マイル先
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
被験者募集中
- Houston Center For Advanced Psychiatric Treatment, Houston
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Houston
Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder
被験者募集中健康なボランティア歓迎
- Michael E. DeBakey VA Medical Center, Houston
- The University of Texas health Science Center at Houston, Houston
他の都市における大うつ病性障害の試験
- New York City, NY37件の研究
- Boston, MA31件の研究
- Atlanta, GA25件の研究
- Philadelphia, PA23件の研究
- Orlando, FL19件の研究
- Miami, FL18件の研究
- Chicago, IL17件の研究
- Tampa, FL17件の研究
- San Diego, CA16件の研究
- Little Rock, AR14件の研究
- Orange, CA13件の研究
- Austin, TX13件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。